Angiology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

http://mc.manuscriptcentral.com/ang

Click here for free access to the SAGE eReference platform!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0003319707305407v1
59/3/352    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Google Scholar
Right arrow Articles by Flota-Cervera, F.
Right arrow Articles by Berber, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flota-Cervera, F.
Right arrow Articles by Berber, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on July 1, 2008
Angiology, Vol. 59, No. 3, 352-356 (2008)
DOI: 10.1177/0003319707305407

Randomized, Double Blind, Placebo-Controlled Clinical Trial to Evaluate the Lymphagogue Effect and Clinical Efficacy of Calcium Dobesilate in Chronic Venous Disease

Fernando Flota-Cervera, MD

Centro de Diagnostico de Enfermedades Cardiovasculares, Merida, Yucatan

Cintia Flota-Ruiz, MD

Centro de Diagnostico de Enfermedades Cardiovasculares, Merida, Yucatan

Carlos Treviño, MD

Grunenthal de México SA de CV, México D.F. Mexico

Arturo Berber, MD, PhD

Grunenthal de México SA de CV, México D.F. Mexico, arturoberber{at}aol.com

The aims of the present study were to investigate the effect of calcium dobesilate on lymph flow and lymphovenous edema in patients with chronic venous disease. It was a randomized, placebo-controlled, double-blind clinical trial. Patients received 1 capsule of 500 mg calcium dobesilate every 8 hours (1.5 g/day) or placebo by 49 days. By the end of the treatment period, only the patients treated with calcium dobesilate had normalization of lymphogammagraphy (capture index and speed of lymph flow; 80 and 78%, respectively). Only patients treated with calcium dobesilate had statistically significant reduction in the perimeter of leg, calf, and ankle. Twenty-two out of 25 (88%) calcium dobesilate—treated patients presented clinical improvement versus 5 out of 24 (20.8%) in the placebo group. One patient on calcium dobesilate developed rash and one patient on placebo complained of vomiting. In the present study, calcium dobesilate normalized lymph physiology and improved symptoms in patients with chronic venous disease.

Key Words: chronic venous disease • calcium dobesilate • lymph • edema • lymphogammagraphy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?